RenovoRx (RNXT) Accounts Payables (2020 - 2026)
RenovoRx (RNXT) posted Accounts Payables of $1.1 million for Q1 2026, up 40.05% sequentially from $799000.0 in Q4 2025, and up 15.72% YoY from $967000.0 in Q1 2025.
RenovoRx (RNXT) Accounts Payables (2020 - 2026) Analysis & Trends
RenovoRx has reported Accounts Payables for 7 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Accounts Payables rose 15.72% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 15.72% YoY) and the FY2025 annual result came in at $799000.0, up 36.35% from the prior year.
- Accounts Payables improved to $1.1 million in Q1 2026 per RNXT's latest filing, from $799000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $1.1 million in Q1 2026 and troughed at $350000.0 in Q3 2023.
- A 5-year average of $669176.5 and a median of $671000.0 in 2025 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables surged 304.51% in 2022, then tumbled 57.0% in 2024.
- Over 5 years, Accounts Payables stood at $534000.0 in 2022, then grew by 5.06% to $561000.0 in 2023, then increased by 4.46% to $586000.0 in 2024, then soared by 36.35% to $799000.0 in 2025, then soared by 40.05% to $1.1 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.1 million, $799000.0, and $869000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 35.57 Mn |
| 10 | RenovoRx | 60.78 Mn | 60.78 Mn | 766,000.00 | 866,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 866,000.00 |
| Mar 31, 2026 | 1.12 Mn |
| Dec 31, 2025 | 799,000.00 |
| Sep 30, 2025 | 869,000.00 |
| Jun 30, 2025 | 671,000.00 |
| Mar 31, 2025 | 967,000.00 |
| Dec 31, 2024 | 586,000.00 |
| Sep 30, 2024 | 686,000.00 |
| Jun 30, 2024 | 438,000.00 |
| Mar 31, 2024 | 356,000.00 |
| Dec 31, 2023 | 561,000.00 |
| Sep 30, 2023 | 350,000.00 |
| Jun 30, 2023 | 872,000.00 |
| Mar 31, 2023 | 828,000.00 |
| Dec 31, 2022 | 534,000.00 |
| Sep 30, 2022 | 538,000.00 |
| Jun 30, 2022 | 473,000.00 |
| Mar 31, 2022 | 729,000.00 |
| Dec 31, 2021 | 525,000.00 |
| Sep 30, 2021 | 133,000.00 |